YJL156W-A Antibody

What is YJL156W-A antibody and what target does it recognize?

YJL156W-A antibody targets the protein product of the YJL156W-A open reading frame (ORF) in yeast. This locus is annotated as a dubious gene that overlaps with the 3' end of the essential gene RPL7A, which encodes the 60S ribosomal protein L7-A. The antibody's specificity comes into question due to this genomic overlap, which creates potential for cross-reactivity with RPL7A protein products.

What is the current availability status of YJL156W-A antibody?

Based on current research databases, no commercial vendors actively list YJL156W-A antibody in their catalogs. Its documented usage appears limited to a single research screen, making it exceptionally rare compared to well-characterized antibodies targeting other yeast proteins. Researchers interested in this antibody would likely need to develop it in-house or collaborate with specialized antibody development services.

What applications has YJL156W-A antibody been used for in published research?

A chemical screening study briefly referenced YJL156W-A antibody usage in ER-to-Golgi transport assays. In this context, the antibody was used alongside anti-TH polyclonal antibodies in immunoblotting protocols. The associated transcript analysis showed a 1.43-fold change, though p-values were not specified in the available documentation. No other published applications have been documented to date.

How does YJL156W-A antibody compare to validated antibodies in terms of characterization?

The characterization of YJL156W-A antibody is significantly limited compared to validated antibodies such as YFV-136. A comparative analysis reveals substantial gaps:

This comparison highlights the significant validation gap for YJL156W-A antibody, which lacks standard characterization metrics typically expected for research-grade antibodies .

What validation challenges exist for YJL156W-A antibody in experimental applications?

YJL156W-A antibody faces multiple validation challenges that impact experimental reliability. First, target ambiguity exists due to the genomic overlap between YJL156W-A and RPL7A genes, creating uncertainty about epitope specificity. Second, critical validation data is absent, including western blot band patterns, immunofluorescence localization patterns, and ELISA performance metrics. Without knockout controls or epitope mapping, researchers cannot conclusively determine antibody specificity. These validation gaps significantly limit confidence in experimental outcomes using this antibody .

How might researchers address cross-reactivity concerns with YJL156W-A antibody?

To address cross-reactivity concerns, researchers should implement a multi-faceted validation approach. First, perform side-by-side Western blot experiments with wild-type and YJL156W-A knockout cell extracts, similar to methodologies used for APP antibody validation. Second, complement antibody-based detection with orthogonal methods such as mass spectrometry to confirm protein identity. Third, conduct epitope mapping to determine which protein regions the antibody recognizes, which would help differentiate between YJL156W-A and RPL7A binding. Finally, pre-absorption experiments with recombinant proteins could quantify cross-reactivity percentages .

What experimental controls are essential when using YJL156W-A antibody for the first time?

When using YJL156W-A antibody for the first time, several controls are essential for establishing reliable protocols:

• Genetic controls: Include wild-type, YJL156W-A knockout, and RPL7A knockdown samples to distinguish specific from non-specific binding

• Peptide competition assays: Pre-incubate antibody with the immunizing peptide to confirm epitope specificity

• Secondary antibody-only controls: Evaluate background signal independent of primary antibody

• Positive controls: Include well-characterized antibodies against established yeast proteins in parallel

• Cross-species validation: Test reactivity against homologous proteins in related yeast species

These controls help establish a baseline for antibody performance and enable researchers to interpret results with appropriate confidence levels .

How can active learning approaches improve antibody validation for targets like YJL156W-A?

Active learning methodologies offer promising approaches for antibody validation in cases like YJL156W-A where limited data exists. These approaches can iteratively improve antibody characterization by:

• Starting with a small labeled subset of data (initial binding experiments)

• Using machine learning to identify the most informative next experiments

• Iteratively expanding the labeled dataset based on prediction uncertainty

• Reducing the total number of experiments needed for comprehensive characterization

Recent research demonstrates that active learning strategies can reduce the number of required antigen mutant variants by up to 35% and accelerate the learning process by 28 steps compared to random experimental selection. For YJL156W-A antibody validation, this approach could efficiently address specificity questions while minimizing resource investment .

What standardized protocol would be recommended for using YJL156W-A antibody in Western blot applications?

Based on successful protocols used for other yeast protein antibodies, a standardized Western blot protocol for YJL156W-A antibody should include:

• Sample preparation: Harvest yeast cells in mid-log phase, perform mechanical lysis with glass beads in buffer containing protease inhibitors

• Protein separation: Resolve 20-40 μg total protein on 10-15% SDS-PAGE gels

• Transfer: Use PVDF membrane with semi-dry transfer at 15V for 30 minutes

• Blocking: 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Incubate with YJL156W-A antibody at 1:500-1:2000 dilution overnight at 4°C

• Secondary antibody: HRP-conjugated anti-species antibody at 1:5000 for 1 hour

• Detection: Enhanced chemiluminescence with exposure times ranging from 30 seconds to 5 minutes

• Controls: Include wild-type and YJL156W-A knockout samples in adjacent lanes

This protocol should be optimized for each specific application, with particular attention to antibody dilution and incubation conditions .

How can researchers evaluate the performance of YJL156W-A antibody for immunoprecipitation?

To evaluate YJL156W-A antibody performance in immunoprecipitation experiments, researchers should follow a systematic approach:

• Input control: Set aside 5-10% of pre-cleared lysate to verify target protein presence

• Immunoprecipitation: Incubate antibody with cell lysate (typically 1-5 μg antibody per 500 μg protein)

• Multiple capture methods: Test both protein A/G beads and direct antibody conjugation approaches

• Immunodepletion analysis: Analyze both precipitate and depleted supernatant fractions

• Western blot verification: Probe immunoprecipitates with a second antibody targeting a different epitope (if available)

• Mass spectrometry validation: Identify all co-precipitated proteins to assess specificity

This comprehensive approach, similar to that used for APP antibody evaluation, provides a complete picture of antibody performance in complex protein mixtures .

What alternative approaches can be used when YJL156W-A antibody shows validation issues?

When validation issues arise with YJL156W-A antibody, researchers can pursue several alternative approaches:

• Epitope tagging: Generate yeast strains expressing YJL156W-A with FLAG, HA, or GFP tags for detection with validated tag-specific antibodies

• CRISPR-based labeling: Employ endogenous protein tagging through CRISPR/Cas9 genome editing

• Proximity labeling: Use BioID or APEX2 fusion proteins to identify proximal proteins without direct antibody detection

• Mass spectrometry: Implement label-free or isotope-labeled quantitative proteomics to track protein expression

• RNA-based detection: Monitor transcript levels using RT-qPCR or RNA-seq as a proxy for protein expression

These approaches circumvent the limitations of poorly characterized antibodies while still enabling research on the protein of interest .

How should researchers interpret contradictory results between YJL156W-A antibody and other detection methods?

When faced with contradictory results between YJL156W-A antibody-based detection and other methods, researchers should implement a structured analysis approach:

• Epitope accessibility assessment: Determine if protein conformation or post-translational modifications might mask epitopes under certain conditions

• Detection method comparison: Systematically compare results from multiple detection methods (Western blot, immunofluorescence, mass spectrometry)

• Contextual analysis: Evaluate results in the context of biological conditions (stress, growth phase, genetic background)

• Statistical validation: Apply appropriate statistical tests to determine significance of observed differences

• Literature reconciliation: Compare findings with any available literature on YJL156W-A and RPL7A

The guiding principle should be that convergent evidence from multiple methodologies provides greater confidence than any single detection method, particularly when using antibodies with limited validation data .

What potential biological insights could YJL156W-A antibody provide despite its limitations?

Despite its limitations, YJL156W-A antibody could theoretically help study several important biological phenomena:

• Ribosomal protein processing: Investigate potential overlapping functions with RPL7A in ribosome assembly

• Gene overlap phenomena in yeast: Explore the significance of genomic overlaps and their evolutionary implications

• Artifacts in high-throughput screens: Understand false positives in large-scale protein interaction studies

• Transcriptional and translational regulation: Examine how dubious ORFs might be expressed under specific conditions

• Stress response mechanisms: Investigate potential expression changes under various cellular stresses

These applications would require rigorous controls and complementary methodologies to compensate for the antibody's validation gaps.

How can the lessons from YJL156W-A antibody inform antibody selection for other poorly characterized proteins?

The challenges associated with YJL156W-A antibody offer valuable lessons for antibody selection in other poorly characterized proteins:

• Prioritize antibodies with knockout validation data, preferably in multiple cell lines or organisms

• Seek antibodies with established epitope mapping to predict potential cross-reactivity

• Review raw validation data rather than relying on manufacturer claims alone

• Consider the genomic context of target proteins (overlapping genes, alternative splicing, etc.)

• Evaluate antibody performance across multiple applications rather than a single use case

These principles align with standardized antibody validation initiatives that aim to improve reproducibility in life science research through more rigorous antibody characterization .